We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 49.02 | 49.93 | 49.595 | 48.97 | 49.48 | 1,113,911 | 22:58:03 |
From May 2019 to May 2024
By Cecilia Butini
Sanofi SA said Thursday that net profit grew on year in the third quarter and that it has raised its business earnings per share guidance for the year.
The French pharmaceutical major posted net profit of 1.95 billion euros ($2.29 billion) for the period, up from EUR1.77 billion the year prior.
Sales fell slightly to EUR9.48 billion compared with EUR9.50 billion the year prior, but were driven by strong performance of monoclonal antibody Dupixent and demand for flu vaccines, the company said.
Business net income--a metric which Sanofi uses to indicate income without certain one-off items--came in at EUR2.30 billion, up from EUR2.28 billion in the third quarter of 2019.
The company raised its business EPS guidance. It now expects 2020 business EPS to grow between 7% and 8% at constant exchange rates, having previously guided for EPS growth between 6% and 7% at constant exchange rates.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 29, 2020 03:12 ET (07:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
